Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cardiol Therapeutics Inc. (CRDL : NSDQ)

• Company Description    Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $1.37 Daily Weekly Monthly 20 Day Moving Average: 182,717 shares Shares Outstanding: 82.65 (millions) Market Capitalization: $113.23 (millions) Beta: 1.04 52 Week High: $2.63 52 Week Low: $0.77 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.86% -8.42% 12 Week 35.64% 14.09% Year To Date 7.03% 0.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2265 UPPER MIDDLE ROAD EAST SUITE 602 - OAKVILLE,A6 L6H 0G5 CAN ph: 289-910-0850 fax: - trevor.burns@cardiolrx.com http://www.cardiolrx.com

• General Corporate Information    Officers David Elsley Ontario - Chief Executive Officer; President and Director Guillermo Torre - Chairman Bernard Lim - Chief Operating Officer Chris Waddick - Chief Financial Officer and Corporate Secretary Andrew Hamer - Chief Medical Officer and Head of Research and Dev Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 14161Y200 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 82.65 Most Recent Split Date: (:1) Beta: 1.04 Market Capitalization: $113.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 9.24 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 30.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -209.63 12/31/24 - -207.02 ROA 06/30/25 - - 03/31/25 - -141.09 12/31/24 - -136.75 Current Ratio 06/30/25 - - 03/31/25 - 3.26 12/31/24 - 4.52 Quick Ratio 06/30/25 - - 03/31/25 - 3.26 12/31/24 - 4.52 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.15 12/31/24 - 0.22 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.01 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.66 12/31/24 - 0.51

Powered by Zacks Investment Research ©